Ironshore Pharmaceuticals Completes US$200 Million Financing
|Areas||Banking and Finance Law, Corporate Finance and Securities, Intellectual Property , Tax, Technology|
Goodmans represented Ironshore Pharmaceuticals & Development, Inc. (“Ironshore”), a wholly owned subsidiary of Highland Therapeutics Inc., in the completion of a US$200 million private placement of Senior Secured Notes due 2024. Morgan Stanley & Co. LLC acted as sole placement agent for the transaction.
The proceeds from the financing will provide the necessary resources for Ironshore to complete its evolution from a research and development organization to a fully integrated pharmaceutical company with a world-class Medical Affairs function. The proceeds will also fund pre-commercialization marketing strategies and tactics as well as commercial launch activities for HLD200, a new drug that manages attention deficit hyperactivity disorder (ADHD) which is under review and awaiting approval by the U.S. Food and Drug Administration.